MENLO PARK, Calif.--(BUSINESS WIRE)--Oct. 27, 2020--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in the following upcoming investor conferences.
- 29th Annual Credit Suisse Virtual Healthcare Conference
Presenting on Tuesday, November 10, 2020 at 4:15 p.m. Eastern Time
- Oppenheimer Fall MedTech Summit
Participating on Thursday, November 12, 2020
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue or blood sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over two million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
View source version on businesswire.com: https://www.businesswire.com/news/home/20201027005148/en/
Investor Relations Contact:
Source: Personalis, Inc.